Trial Profile
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Food Effect of Single Ascending Doses and Multiple Ascending Doses of EHP-101 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Etrinabdione (Primary)
- Indications Multiple sclerosis; Systemic scleroderma
- Focus Adverse reactions; First in man
- Sponsors Emerald Health Pharmaceuticals
- 19 Feb 2020 According to an Emerald Health Pharmaceuticals media release, data from this study will be presented at the upcoming ACTRIMS(Americas Committee for Treatment and Research in Multiple Sclerosis) Forum 2020.
- 13 Jan 2020 According to an Emerald Health Pharmaceuticals media release, the company plans to announce the full data from this Phase 1 study in February at a prestigious medical meeting.
- 26 Aug 2019 According to an Emerald Health Pharmaceuticals Media release, the company plans to announce top-line results from this study before end of 2019, once the data are fully analyzed, and will be submitting the study results for presentation at upcoming international conferences.